Australia's largest stock trading and investment forum Australia's #1 stock forum

IHL

0.00%

4.1¢ incannex healthcare limited

Ann: RESUBMISSION - Quarterly Update and Appendix 4C, page-32

First 32 Last

Share
Profile

Follow
Glitterati

10,271 Posts.

2805

02/02/20

17:21

Post #: 42702537
Share

Originally posted by rhino78: ↑

Hi all, in the second paragraph of the quarterly it mentions “these activities are expected to accelerate over the CURRENT quarter over 4 cannabinoid clinical projects”.

I d suggest more announcements are on the way in the not to distant future as they all come on line.

I understand they didn’t mention gingerv in the update specifically but perhaps it has its own update soon.

While I think it would be great if the SP was much higher, I honestly feel as all these trials come online and start proving themselves, things will really move and that is the time to really promote IHL when there is more proof. The sells Friday was on tiny volume.

Medicine as most of us know needs to be evidence based, IHL already has anecdotal evidence which is why a lot of us are here but if we get trial evidence which I believe we will, everyone will know about it very quickly.

I d also say we are late this year or early next at best before anything like a TO is a possibility. Personally my timeline is mid to late 2021 before IHL worth what it can be worth if things go to plan.

I did speak to management on the phone late last year as I hold a fair few aswell and found them very approachable and well worth having a chat too. (It did take 2/3 weeks to find a suitable time to chat) which was no issue to me as they are clearly very busy getting everything rolling.

They mentioned the oils sales was nothing to get excited about, margins are not great because there is lots of competition, (Again most here understand this already). However being able to sell the 4 trials through the SAS as they progress is very exciting when/if it happens because particularly for OSA and TBI there is NO competition. They did not tell me anything I did not know but it is good to talk and hear the line of thinking etc.
The CEO from Roche has been outstanding from what they said aswell, excellent and getting things done quicker than they ever have.

I believe the big reason Peloton like it so much is the drug IP for the 4 drugs we are are trying to bring to market.

IHL is also up from about 2c to 6.5c in 12 months (approx) which is solid.

Lastly I think the 4C was great, keep in mind people like myself will be very highly likely exercising their options July/aug so that will add a heap more cash to the balance sheet.

As we all have to say it is all my opinions etc.

It has been a slow 4 months since late Sept for holders so I understand how some are getting frustrated.
Personally I am more confident than I have ever been about IHL.

Expand

Good post Rhino,......no doubt that the trials are the big attraction for Peloton, agree with you 100%.

If they were looking at CBD sales, there are any number of companies they could have loaded up on. The risk/reward here is very attractive.....even 1 successful trial will result in the MC being many times higher than it is today, especially if it's OSA or TBI IMO. I see blue sky as far as the eye can see if 3 or 4 trials go our way

IHL Price at posting: 6.4¢ Sentiment: Buy Disclosure: Held
5 Upvote

0 Great analysis

Reply

Top Stories

EBR

EBR Systems' heart pacing device on-target to reach the US market

BOE

Boss Energy ramps up as industrial-scale plant build continues; FY25 guidance of 850Klb intact

SKS

SKS secures $20M for extension works on Melbourne data centre

Is the ASX getting its groove back? Here's 5 IPOs in September to watch

GDP grows 0.2% in June quarter, but annual growth the slowest since the 1990s